Loading...
SNTI logo

Senti Biosciences Holdings, Inc.NasdaqCM:SNTI Stock Report

Market Cap US$30.7m
Share Price
US$0.99
US$11.25
91.2% undervalued intrinsic discount
1Y-70.0%
7D12.7%
1D
Portfolio Value
​
View

Senti Biosciences Holdings, Inc.

NasdaqCM:SNTI Stock Report

Market Cap: US$30.7m

Senti Biosciences Holdings (SNTI) Stock Overview

A clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. More details

SNTI fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health1/6
Dividends0/6

Rewards

Revenue is forecast to grow 72.98% per year

Risk Analysis

Has less than 1 year of cash runway

Makes less than USD$1m in revenue ($38K)

Currently unprofitable and not forecast to become profitable over the next 3 years

Volatile share price over the past 3 months compared to the US market

+ 2 more risks

SNTI Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Senti Biosciences Holdings, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Senti Biosciences Holdings
Historical stock prices
Current Share PriceUS$0.99
52 Week HighUS$3.88
52 Week LowUS$0.77
Beta2.1
1 Month Change-8.97%
3 Month Change4.99%
1 Year Change-70.02%
3 Year Change-89.56%
5 Year Change-99.01%
Change since IPO-99.01%

Recent News & Updates

Recent updates

Analysis Article • Dec 28

Is Senti Biosciences (NASDAQ:SNTI) In A Good Position To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analysis Article • Sep 27

Will Senti Biosciences (NASDAQ:SNTI) Spend Its Cash Wisely?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Sep 22

Senti Biosciences initiated at buy at Chardan on gene circuit synthetic biology platform

Chardan Capital Markets has initiated Senti Biosciences (NASDAQ:SNTI) with a buy highlighting the potential of the company's gene circuit synthetic biology platform and engineered cell therapy pipeline. The firm says the platform and pipeline can "address several limitations of current cell and gene therapy modalities." Chardan has a price target of $12 (757% upside based on Thursday's close). "Senti (SNT) has developed a suite of technologies including logicgates, calibrated-release cytokines, small-molecule regulated promoters....[that] can be used independently or in concert to achieve an optimized therapeutic profile across multiple modalities including various engineered cell therapy types as well as viral vectors," Chardan analyst wrote. Senti has two candidates based on donor-derived CAR-NK cells: SENTI-202 for acute myeloid leukemia, and SENTI-301 for hepatocellular carcinoma. Both are expected to enter the clinic next year.
Seeking Alpha • Aug 16

Senti Biosciences GAAP EPS of -$0.86, revenue of $1.36M

Senti Biosciences press release (NASDAQ:SNTI): Q2 GAAP EPS of -$0.86. Revenue of $1.36M (+72.2% Y/Y). As of June 30, 2022, Senti Bio held cash and cash equivalents of $139.8M, which the company believes is sufficient to fund operations into 2024.
Analysis Article • Jun 13

Is Senti Biosciences (NASDAQ:SNTI) In A Good Position To Invest In Growth?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Shareholder Returns

SNTIUS BiotechsUS Market
7D12.7%2.9%2.5%
1Y-70.0%33.0%26.4%

Return vs Industry: SNTI underperformed the US Biotechs industry which returned 34.6% over the past year.

Return vs Market: SNTI underperformed the US Market which returned 28.7% over the past year.

Price Volatility

Is SNTI's price volatile compared to industry and market?
SNTI volatility
SNTI Average Weekly Movement11.3%
Biotechs Industry Average Movement10.8%
Market Average Movement7.2%
10% most volatile stocks in US Market16.5%
10% least volatile stocks in US Market3.1%

Stable Share Price: SNTI's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: SNTI's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201639Tim Luwww.sentibio.com

Senti Biosciences Holdings, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The company’s lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need. It offers SENTI-202, a logic gated off-the-shelf CAR-NK cell therapy for the treatment of blood cancers and relapsed/refractory hematological malignancies, including acute myeloid leukemia.

Senti Biosciences Holdings, Inc. Fundamentals Summary

How do Senti Biosciences Holdings's earnings and revenue compare to its market cap?
SNTI fundamental statistics
Market capUS$30.74m
Earnings (TTM)-US$51.55m
Revenue (TTM)US$38.00k
813.2x
P/S Ratio
-0.6x
P/E Ratio

Is SNTI overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SNTI income statement (TTM)
RevenueUS$38.00k
Cost of RevenueUS$37.59m
Gross Profit-US$37.55m
Other ExpensesUS$14.00m
Earnings-US$51.55m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)-1.66
Gross Margin-98,810.53%
Net Profit Margin-135,650.00%
Debt/Equity Ratio516.9%

How did SNTI perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/26 15:45
End of Day Share Price 2026/05/26 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Senti Biosciences Holdings, Inc. is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Gregory HarrisonBofA Global Research
Yevgeniya LivshitsChardan Capital Markets, LLC
Emily BodnarH.C. Wainwright & Co.